May 29 (Reuters) - Mesoblast Ltd MSB.AX :
* MESOBLAST INITIATES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION (BLA) TO U.S. FDA FOR REMESTEMCEL-L IN THE TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE
* MESOBLAST - PHASE 3 TRIAL MET PRIMARY ENDPOINT OF INCREASED DAY 28 OVERALL RESPONSE COMPARED WITH A PROTOCOL-DEFINED HISTORICAL CONTROL RATE OF 45%
* MESOBLAST - FDA AGREED TO ROLLING REVIEW OF BLA WHICH ENABLES INDIVIDUAL COMPONENTS TO BE SUBMITTED, REVIEWED ON ONGOING BASIS